Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease is under clinical development by MassBiologics and currently in Phase I for Lyme Disease. According to GlobalData, Phase I drugs for Lyme Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease overview
Monoclonal antibodies are under development for the prevention of Lyme disease. The therapeutic candidates are a HuMabs act by targeting the outer surface protein A (ospA). It is administered through subcutaneous route.
MassBiologics a Biotechnology company which develops and manufactures vaccines and other biologic products. The company operates vaccines to improve public health through applied research, development and production of biologic products, including vaccines, plasma derivatives and most recently, monoclonal antibodies. The company is headquartered in Boston, Massachusetts, the United States.
For a complete picture of Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease’s drug-specific PTSR and LoA scores, buy the report here.